Nathaniel Spicer
A5015854069- Neuroblastoma Research and Treatments
- CAR-T cell therapy research
- Immune Cell Function and Interaction
- Cancer Research and Treatments
- interferon and immune responses
- Immune cells in cancer
- Immunotherapy and Immune Responses
- Advanced Biosensing Techniques and Applications
- Cancer Cells and Metastasis
- Occupational and environmental lung diseases
- Virus-based gene therapy research
- Cancer Immunotherapy and Biomarkers
- T-cell and B-cell Immunology
- Monoclonal and Polyclonal Antibodies Research
Dartmouth College
2024
Dana-Farber Cancer Institute
2022-2024
Activation of the stimulator interferon genes (STING) pathway promotes antitumor immunity but STING agonists have yet to achieve clinical success. Increased understanding mechanism action in human tumors is key developing therapeutic combinations that activate effective innate immunity. Here, we report malignant pleural mesothelioma cells robustly express and are responsive agonist treatment ex vivo. Using dynamic single-cell RNA sequencing explants treated with a agonist, observed CXCR3...
Overcoming immune suppression is a major barrier to eliciting potent CD8
Abstract Preclinical and clinical studies have used antibodies to deplete CD4-expressing cells promote anti-tumor immunity. Specifically, a monoclonal anti-CD4 antibody (anti-CD4) has been employed remove FOXP3+ CD4+ regulatory T (Tregs), which are known impede Our previous demonstrated that administering during B16 melanoma tumor growth in mice leads the generation of Ag-specific CD8 disseminate form memory following surgical excision. However, importance co-depleting other cell...
Abstract Background: Collective evidence highlights that agonism of the host STING pathway plays a critical role in eliciting robust and durable anti-tumor immunity. Dazostinag (TAK-676) is novel systemically delivered agonist ignites innate immune system mobilizes adaptive Preclinical studies with dazostinag demonstrated strong, persistent CD8+ T cell response driven by derived type I IFN pro-inflammatory cytokines. The cells to was further supported previously correlation between frequency...
Abstract Background: Increasing the immunogenicity of solid tumors may potentiate durable anti-tumor immunity. Targeting innate pattern recognition receptor signaling is a promising strategy to repolarizing suppressive tumor immune microenvironment (TME). A potential synergistic approach addition cellular therapy. Tumor models expressing high levels endogenous STING, but where pathway not active, were considered for evaluating STING agonism as intervention. Additionally, prior work has...
<div>Abstract<p>Activation of the stimulator interferon genes (STING) pathway promotes antitumor immunity but STING agonists have yet to achieve clinical success. Increased understanding mechanism action in human tumors is key developing therapeutic combinations that activate effective innate immunity. Here, we report malignant pleural mesothelioma cells robustly express and are responsive agonist treatment <i>ex vivo</i>. Using dynamic single-cell RNA sequencing...
<div>Abstract<p>Activation of the stimulator interferon genes (STING) pathway promotes antitumor immunity but STING agonists have yet to achieve clinical success. Increased understanding mechanism action in human tumors is key developing therapeutic combinations that activate effective innate immunity. Here, we report malignant pleural mesothelioma cells robustly express and are responsive agonist treatment <i>ex vivo</i>. Using dynamic single-cell RNA sequencing...
Supplementary Data from Activation of Tumor-Cell STING Primes NK-Cell Therapy
Supplementary Data from Activation of Tumor-Cell STING Primes NK-Cell Therapy
Abstract Background: Activation of the anti-viral STING pathway promotes antitumor immunity but agonists have yet to achieve clinical success. Understanding their mechanism action in human tumors is key developing STING-based therapies and combinations. Higher tumor expression correlates with better response treatment multiple cancers been shown silence downstream interferon avoid immune detection, demonstrating an important role for cell immunity. Recent mouse studies explored complex...
Abstract Background: Immune cell trafficking into solid tumors has proven challenging due to immune exclusion by vascular barriers. Additionally, testing next-generation therapies remains difficult in animal models and requires sophisticated ex vivo systems study human tumor biology predict treatment response real time. SCLC comprises approximately 15% of all lung cancer cases despite recent incorporation checkpoint blockade (ICB) first line treatment, patients with continue have a poor...